RVMD missed EPS expectations by 11.24%
Nov 05, 2025, 11:35 PM
0.00%
What does RVMD do
Revolution Medicines, a clinical-stage precision oncology firm based in Redwood City, California, focuses on developing targeted therapies, including RAS(ON) inhibitors and companion inhibitors, currently in clinical development. The company went public on February 13, 2020, and employs 411 staff.
Revolution Medicines (RVMD) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Revolution Medicines's actual EPS was -$1.61, missing the estimate of -$1.45 per share, resulting in a -11.24% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.